The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. LAVA Therapeutics NV shares valued at $540,291 were sold by Versant Venture Capital VI, L. on Sep 17 ’25. At $1.49 per share, Versant Venture Capital VI, L. sold 362,806 shares. The insider’s holdings dropped to 2,736,644 shares worth approximately $4.02 million following the completion of this transaction.
Also, Versant Venture Capital VI, L. sold 366,111 shares, netting a total of over 527,859 in proceeds. Following the sale of shares at $1.44 each, the insider now holds 2,370,533 shares.
Before that, Versant Venture Capital VI, L. had sold 307,707 shares from its account. In a trade valued at $471,776, the 10% Owner traded LAVA Therapeutics NV shares for $1.53 each. Upon closing the transaction, the insider’s holdings decreased to 307,707 shares, worth approximately $4.56 million.
As published in a research note from Leerink Partners on December 12, 2024, LAVA Therapeutics NV [LVTX] has been rated down from an Outperform to a Market perform and the price target has been revised to $2 from $11. Analysts at JMP Securities downgraded the stock from ‘”a Mkt outperform”‘ to ‘”a Mkt perform”‘ outlook in a report released in mid December. As of October 25, 2022, H.C. Wainwright has initiated its “Buy” rating for LVTX. Earlier on April 19, 2021, SVB Leerink initiated its rating. Their recommendation was “an Outperform” for LVTX stock.
Analyzing LVTX Stock Performance
On last trading session, LAVA Therapeutics NV [NASDAQ: LVTX] plunged -2.00% to $1.47. The stock’s lowest price that day was $1.43, but it reached a high of $1.55 in the same session. During the last five days, there has been a drop of approximately -4.55%. Over the course of the year, LAVA Therapeutics NV shares have dropped approximately -14.34%.
Is LAVA Therapeutics NV subject to short interest?
Stocks of LAVA Therapeutics NV saw a sharp rise in short interest on 2025-08-29 jumping by 51688.0 shares to 88902.0. Data from Yahoo Finance shows that the short interest on 2025-07-31 was 37214.0 shares. A jump of 58.14% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 0.47 of the overall float, the days-to-cover ratio (short ratio) jumped to 0.47.
Which companies own the most shares of LAVA Therapeutics NV (LVTX)?
Analysts anticipate LAVA Therapeutics NV stock to reach 1.5 by 2025, with the lowest price target being 1.5. In spite of this, 2 analysts ranked LAVA Therapeutics NV stock as Buy at the end of 2025. On April 19, 2021, JP Morgan assigned a price target of “an Overweight” to the stock and initiated coverage with a $22.
